title: BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection.
abstract: An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm(2) sterile ureteral stents were incubated in 1mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations. Experiments were performed in duplicate. Ureteral stents were explanted at day 5 following implantation and biofilm bacteria enumerated. Our data showed that rats that received intraperitoneal vancomycin showed the lowest bacterial numbers. BMAP-28 combined with vancomycin showed efficacies higher than that of each single compound. These results highlight the potential usefulness of this combination in preventing ureteral stent-associated in gram-positive infections.
authors.affiliation: Experimental Animal Models for Aging Units, Research Department, I.N.R.C.A.-I.R.R.C.S., Ancona, Italy.
authors.forename: Fiorenza
authors.initials: F
authors.lastname: Orlando
authors.forename: Roberto
authors.initials: R
authors.lastname: Ghiselli
authors.forename: Oscar
authors.initials: O
authors.lastname: Cirioni
authors.forename: Daniele
authors.initials: D
authors.lastname: Minardi
authors.forename: Linda
authors.initials: L
authors.lastname: Tomasinsig
authors.forename: Federico
authors.initials: F
authors.lastname: Mocchegiani
authors.forename: Carmela
authors.initials: C
authors.lastname: Silvestri
authors.forename: Barbara
authors.initials: B
authors.lastname: Skerlavaj
authors.forename: Alessandra
authors.initials: A
authors.lastname: Riva
authors.forename: Giovanni
authors.initials: G
authors.lastname: Muzzonigro
authors.forename: Vittorio
authors.initials: V
authors.lastname: Saba
authors.forename: Giorgio
authors.initials: G
authors.lastname: Scalise
authors.forename: Margherita
authors.initials: M
authors.lastname: Zanetti
authors.forename: Andrea
authors.initials: A
authors.lastname: Giacometti
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D018441:Biofilms; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D008970:Molecular Weight; D011506:Proteins / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D015607:Stents / Q000009:adverse effects; D014513:Ureter / Q000382:microbiology / Q000601:surgery; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; C102360:BMAP-28; D011506:Proteins; D014640:Vancomycin